Scientists Target FVIII Inhibitor Formation in Hemophilia A
Scientists found the immune signaling protein BAFF can promote the formation of neutralizing antibodies, or inhibitors, against blood…
Articles by Steve Bryson, PhD
Switch to Rixubis Not Linked to Increased Bleed Rates in Small Study
For people with hemophilia B, switching to Rixubis (nonacog gamma) as a factor IX…
Esperoct Highly Effective as Prophylaxis for Hemophilia A, Study Suggests
Severe hemophilia A patients using Esperoct (turoctocog alfa pegol) as a preventive…
Most Hemophilia Patients Show Positive Attitude for Gene Therapy in Study
Most people with hemophilia have a positive attitude toward gene therapy, and are willing or “very willing”…
Insurance Firm BCS Partners With NHF to Improve Healthcare Quality, Cost
The healthcare insurance company BCS Financial has partnered with the…
GC Pharma, Atomwise Aim for Potential Oral Hemophilia Therapies
Atomwise, a company that specializes in using artificial intelligence (AI)…
#ISTH2020 – Unmet Medical Need Found in Mild, Moderate Hemophilia A Care
Adults with mild and moderate hemophilia A have a substantial number of bleeds per year as well as joint…
Idelvion Approved in Europe for 21-day Prophylactic Dosing in Adults With Hemophilia B
The European Medicines Agency (EMA) has approved 21-day dosing intervals for…
Sernova Testing AgeX’s UniverCyte Technology to Deliver FVIII to Hemophilia A Patients
Sernova will use AgeX Therapeutics’ UniverCyte…
Gene, Cell Therapy Combo Shows Promise for Treating Hemophilia A, Study Reports
A new combination of gene and cell-based therapy durably delivered therapeutic levels of factor VIII (FVIII) — the blood…